It’s a tie: Sanofi and No­vo come in neck-and-neck at the FDA with two new di­a­betes com­bo OKs

Sanofi and No­vo Nordisk tried might­i­ly to beat each oth­er to the fin­ish line first with a com­bi­na­tion of their long-last­ing in­sulin with their GLP1 drugs. But the FDA de­cid­ed to call it a draw.

Reg­u­la­tors in the US si­mul­ta­ne­ous­ly ap­proved No­vo’s Xul­to­phy — a com­bi­na­tion of Tre­si­ba and Vic­toza on the mar­ket in Eu­rope for the past two years — and Sanofi’s Soli­qua, which com­bines Lan­tus and Lyx­u­mia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER